Categories: News

Vial Announces EMR Integration with Nextech to Power Clinical Trial Patient Recruitment

Vial has announced that the VialConnect integration with Nextech is now live. With VialConnect, research clinics that use Nextech EMR can display patient information relevant to inclusion/exclusion (I/E) criteria such as conditions, medications, and allergies to streamline clinical trial study recruitment for free.

The Nextech integration is available to all clinics running dermatology and ophthalmology clinical trials using VialConnect CTMS. It delivers customizable CTMS (clinical trial management system) that powers core workflows and an EMR filtering tool to sort potential trial subjects from a clinic’s patient database. VialConnect is part of a series of tech-enabled solutions offered by Vial, including EDCeTMF, and eSource.

VialConnect’s EMR filtering capabilities allow for complex querying within a user-friendly UI. Users can sort their database, find eligible subjects, and exclude ineligible ones based on several criteria, including indication, demographics, allergies, and current medications. The functionality is effective for indications with wide and low prevalence. Nextech also provides specific benefits for ophthalmology clinical trials, such as refraction values and OCT scans which further help to refine the patient search.

Vial is next-generation CRO that promises faster execution and high-quality trial outcomes by leveraging Vial’s tech-enabled clinical trial management system, streamlined study startup processes, and proven enrollment playbook. Together, these best-in-class services and operational excellence accelerate the development of new therapies and devices for sponsors.


Published by

Recent Posts

A Look at Jeezy’s Net Worth

At the top of the rap game, Jeezy has made a name for himself as…

2 weeks ago

Uncovering Bob Baffert’s Net Worth: A Comprehensive Look

Bob Baffert is an American horse racing trainer and a three-time winner of the Triple…

2 weeks ago

Arthur J. Gallagher & Co. Announces Regular Fourth Quarter Dividend

Arthur J. Gallagher & Co. (NYSE: AJG) declared a regular quarterly cash dividend of fifty one cents ($0.51) per share…

7 months ago

INVISIO enters into two-year framework agreement with strategically important law enforcement customer in northern Europe

The two-year framework agreement where the end-customer is the country’s National Police concerns communication equipment with hearing…

9 months ago

New number of votes in AB Volvo

The number of votes in AB Volvo has changed due to the conversion of a…

9 months ago

Jordan C. Collier, MD, is recognized by Continental Who’s Who

Jordan C. Collier, MD, is being recognized by Continental Who's Who as a Distinguished Healthcare…

9 months ago